Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Crescent Biopharma (CBIO) Return on Capital Employed (2016 - 2026)

Crescent Biopharma (CBIO) has disclosed Return on Capital Employed for 11 consecutive years, with 0.79% as the latest value for Q1 2026.

  • For Q1 2026, Return on Capital Employed rose 386.0% year-over-year to 0.79%; the TTM value through Mar 2026 reached 0.79%, up 386.0%, while the annual FY2023 figure was 0.94%, 20.0% down from the prior year.
  • Return on Capital Employed hit 0.79% in Q1 2026 for Crescent Biopharma, up from 1.0% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 0.5% in Q3 2025 and bottomed at 4.66% in Q1 2025.
  • Average Return on Capital Employed over 5 years is 1.23%, with a median of 0.95% recorded in 2022.
  • Year-over-year, Return on Capital Employed plummeted -351bps in 2025 and then soared 386bps in 2026.
  • Crescent Biopharma's Return on Capital Employed stood at 1.05% in 2022, then increased by 12bps to 0.93% in 2023, then tumbled by -131bps to 2.14% in 2024, then surged by 53bps to 1.0% in 2025, then rose by 20bps to 0.79% in 2026.
  • According to Business Quant data, Return on Capital Employed over the past three periods came in at 0.79%, 1.0%, and 0.5% for Q1 2026, Q4 2025, and Q3 2025 respectively.